Engrail closes $157M series B, fueled by investors’ renewed interest in neuropsychiatry March 19, 2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies March 19, 2024
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey March 19, 2024
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 12, 2024
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 8, 2024